Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Auswirkungen der Mikronährstoff-Supplementierung vor der Schwangerschaft auf die Ergebnisse von Mutter und Kind

30. September 2026 aktualisiert von: Usha Ramakrishnan, Emory University

The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status.

Studienübersicht

Detaillierte Beschreibung

Low birth weight and anemia remain intractable problems in many developing countries despite considerable efforts to address them. Intervening with just prenatal iron-folate (IFA) supplements may not be the best approach given the substantial demands for iron by maternal and fetal tissues. Therefore, there is an urgent need to evaluate the additional contribution of prepregnancy interventions.

Low birth weight (LBW) and anemia remain public health problems in many developing countries. There is a great deal of evidence in the literature that anemia, primarily due to iron deficiency, has been associated with poor birth outcomes and LBW. The most common interventions is the provision of iron-folate (IFA) supplements during pregnancy. Despite several decades of effort, the success of these interventions in improving anemia and LBW was limited due to: inadequate coverage, high costs and an inability to sustain the programs. Reasons for low effectiveness also include inadequacy of delivery systems, side effects and poor compliance among pregnant women. In addition, intervening with iron-folate (IFA) supplements during pregnancy alone may not be sufficient as many women enter pregnancy with suboptimal iron stores. Weekly pre-pregnancy IFA supplementation (WIFS) has been introduced as a way to reduce the burden of anemia and improve birth outcomes. WIFS has been shown to improve iron status and reduce the burden of anemia in Women of Reproductive Age (WRA) in the short term, but no study has assessed the effects of this intervention on birth outcomes.

The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status. The study will be conducted in Vietnam, a developing country, where anemia and Iron Deficiency (ID) are highly prevalent and will provide valuable scientific evidence that will inform policy. Infants born to women receiving the intervention are followed up to age 10 to 11 to assess periconception nutrition on early adolescent body size, anemic status, cognitive and academic achievement.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

5011

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Thái Nguyên
      • Thai Nguyen, Thái Nguyên, Vietnam, 24000
        • Thai Nguyen University of Medicine and Pharmacy

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 35 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria for Women:

  • 18-35 years old
  • Currently married
  • Currently living in one of the 10 communes and intends to live in the areas for 24 months following recruitment
  • Plans to have children in the next year
  • Agrees to participate with informed consent

Exclusion Criteria for Women:

  • Currently pregnant
  • Delivered in the previous six months
  • Regularly consumed IFA or MM supplements in the past 2 months
  • Severe anemia (Hb < 7 g/L)
  • History of high risk pregnancy including abruptio placenta, placenta previa, gestational diabetes, pregnancy induced hypertension, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use
  • Chronic hematological diseases, hereditary defects of red cells or hemoglobin

Inclusion Criteria for Offspring:

  • Child of a female participant of the original study

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Multiple Micronutrient - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive a supplement that is taken weekly during pre-pregnancy.

There is no current recommendation for weekly MM supplements for WRA. Therefore, the researchers propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/United Nations University (UNU) recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy and contains:

  • 800 μg Vitamin A
  • 600 IU Vitamin D
  • 10 mg Vitamin E
  • 70 mg Vitamin C
  • 1.4 mg Thiamine
  • 1.4 mg Riboflavin
  • 18 mg Niacin
  • 1.9 mg Vitamin B6
  • 2.6 μg Vitamin B12
  • 2800 μg Folic Acid
  • 60 mg Iron
  • 15 mg Zinc
  • 2 mg Copper
  • 65 μg Selenium
  • 150 μg Iodine
Aktiver Komparator: Iron and Folic Acid - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current World Health Organization (WHO) recommendations for WRA.

The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.

Placebo-Komparator: Folic Acid - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.

It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.

Experimental: Multiple Micronutrient - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive a supplement that is taken weekly during pre-pregnancy.

There is no current recommendation for weekly MM supplements for WRA. Therefore, the researchers propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/United Nations University (UNU) recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy and contains:

  • 800 μg Vitamin A
  • 600 IU Vitamin D
  • 10 mg Vitamin E
  • 70 mg Vitamin C
  • 1.4 mg Thiamine
  • 1.4 mg Riboflavin
  • 18 mg Niacin
  • 1.9 mg Vitamin B6
  • 2.6 μg Vitamin B12
  • 2800 μg Folic Acid
  • 60 mg Iron
  • 15 mg Zinc
  • 2 mg Copper
  • 65 μg Selenium
  • 150 μg Iodine
Aktiver Komparator: Iron and Folic Acid - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.

The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.

Placebo-Komparator: Folic Acid - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.

It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Birth Size - Weight
Zeitfenster: At birth

Infant weight is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Weight is measured in grams (g).

At birth
Birth Size - Body Length
Zeitfenster: At birth

Infant length is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Length is measured in millimeters (mm).

At birth
Birth Size - Head Circumference
Zeitfenster: At birth

Infant head circumference is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Head circumference is measured in millimeters (mm).

At birth
Gestational Age
Zeitfenster: At birth

Gestational age is calculated based on the date of last menstrual period. This method has been shown to be reliable in previous work and the researchers expect precise estimates since women will be visited weekly from baseline during the pre-pregnancy period. Women who have delivered babies in the past 6 months are excluded.

At birth
Child length
Zeitfenster: From Birth to 24 months

Child length, measured in millimeters (mm) is measured at birth, 1, 3, 6, 9, 12, 15, 18, and 24 months of age.

From Birth to 24 months
Child weight
Zeitfenster: From birth through 24 months of age

Child weight, measured in grams (g), is measured at birth, 1, 3, 6, 9, 12, 15, 18, and 24 months of age.

From birth through 24 months of age
Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III) Score
Zeitfenster: 12 and 24 months

Child development is measured using the Bayley Scales of Infant and Toddler Development - Third Edition at 12 and 24 months of age. The Bayley-III is a standardized comprehensive assessment tool for assessing child development in children one month to 42 months old. The highest possible scaled score on each subtest is 19, and the lowest possible score is 1. Scores from 8 to 12 are considered average. Index scores for motor and language domains are derived from sums of the subtest scaled scores. Index scores range from 40-160 with higher scores indicating. Composite scores are calculated for the cognitive, language, and motor scales to compare children to a normative age-matched sample. Composite scores have a mean of 100 with a standard deviation of 15. Composite scores below 85 indicate mild cognitive impairment and scores below 70 indicate moderate to severe cognitive impairment.

12 and 24 months
Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Score
Zeitfenster: 6 to 7 years of age, 10 to 11 years of age

Child development is measured using the WISC-IV. This test has been validated and adapted in the Vietnamese context and takes 60-70 minutes to administer. The WISC-IV consists of 10 subtests (Vocabulary, Similarities, Comprehension, Block Design, Picture Concepts, Matrix Reasoning, Digit Span, Letter-Number Sequencing, Coding, and Symbol search). These are summed into four indices: the Verbal Comprehension Index (VCI, a measure of crystallized abilities), Perceptual Reasoning Index (PRI, a measure of inductive and quantitative reasoning), Working Memory Index (WMI, a measure of children's ability to memorize new information), Processing Speed Index (PSI, a measure of the speed of information processing including the ability to focus attention and quickly scan, discriminate and sequentially order visual information). The Full-Scale intelligence quotient (IQ) score ranges from 40 to 160 points with higher scores indicating higher intelligence. Scores of 90 to 109 are considered average.

6 to 7 years of age, 10 to 11 years of age
Weight-for-age Z score (WAZ)
Zeitfenster: 6 to 7 years of age, 10 to 11 years of age

The weight-for-age Z score (WAZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age, 10 to 11 years of age
Height-for-Age Z Score (HAZ)
Zeitfenster: 6 to 7 years of age, 10 to 11 years of age

The height-for-age Z score (HAZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age, 10 to 11 years of age
Weight-for-Height Z Score (WHZ)
Zeitfenster: 6 to 7 years of age

The weight-for-height Z score (WHZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age
Body Mass Index Z Score (BMI-Z)
Zeitfenster: 10 to 11 years of age

The body mass index Z Score (BMI-Z) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

10 to 11 years of age
Body composition (Lean mass/fat free mass index)
Zeitfenster: 6 to 7 years of age, 10 to 11 years of age

Body composition (Lean mass/fat free mass index) in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements

6 to 7 years of age, 10 to 11 years of age

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mothers' iron status
Zeitfenster: At baseline, 1 month postpartum, 3 months postpartum

Venous blood samples (5 ml) will be collected from women at: baseline, the first prenatal visit and at 1 and 3 months post partum. Anemia will be defined as Hb value <12 g/L for non-pregnant women, and <11g/L for pregnant women and infants, and iron deficiency as serum ferritin <12 μg/L (93).

At baseline, 1 month postpartum, 3 months postpartum
Infants' iron status
Zeitfenster: Birth, 3 months of age

Infant iron status is measured in cord blood samples (5 ml) obtained at delivery and at 3 months of age using a capillary blood sample that is obtained from a heel prick. The hemoglobin concentration are measured from a drop of blood using the HEMOCUE B- Hb photometer. The blood samples are then centrifuged and serum samples are aliquoted into microcuvettes and handled in the same way as described for mothers. Serum ferritin and transferrin receptor concentrations will be assayed using the ELISA method.

Birth, 3 months of age
Center for Epidemiological Studies Depression Scale (CES-D) Score
Zeitfenster: At baseline, during pregnancy, 3 months postpartum

Maternal depression is assessed with the Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report instrument asking respondents if they have experienced symptoms of depression during the past week. Responses are given on a scale of 0 to 3 where rarely is scored as 0 and most of the time is scored as 3. Total scores range from 0 to 60 and higher scores indicate greater symptoms of depression.

At baseline, during pregnancy, 3 months postpartum
Edinburgh Postnatal Depression Scale (EPDS) Score
Zeitfenster: At baseline, during pregnancy, 3 months postpartum

Maternal depression is assessed with the Edinburgh Postnatal Depression Scale (EPDS). The EPDS includes 10-items asking participants about symptoms of depression that they have experienced in the past 7 days. Responses are given on a 4-point scale where 0 corresponds with the least amount of symptoms and 3 corresponds with the highest amount of symptoms. Total scores range from 0 to 30 with higher scores indicating increased symptoms of depression. Scores of 10 and greater indicate possible depression.

At baseline, during pregnancy, 3 months postpartum

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Academic Achievement
Zeitfenster: 10 to 11 years of age

Academic achievement is evaluated with an assessment tool that has been used previously in Vietnam as part of the Young Lives Study. Study participants will take assessments in mathematics and Vietnamese (reading) at the beginning of the academic year when they enter Grade 5 in the school setting. Each test will take approximately 45 minutes. The test instruments in both math and reading employ a 30-item multiple-choice format and were developed in consultation with curriculum experts from the Vietnamese National Institute of Educational Sciences and are in line with those employed in the Ministry of Education & Training (MOET)/World Bank Grade 5 Study to measure learning levels in relation to curricular expectations, covering key subject domains at a range of levels of cognitive demand.

10 to 11 years of age

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Oktober 2011

Primärer Abschluss (Tatsächlich)

1. September 2014

Studienabschluss (Tatsächlich)

1. August 2023

Studienanmeldedaten

Zuerst eingereicht

13. August 2012

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. August 2012

Zuerst gepostet (Geschätzt)

15. August 2012

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

2. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren